Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 5/2018

15.05.2018 | Case Report

Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction

verfasst von: Marianna Mavilia, Agnes McAuliffe, Safina Hafeez, Haleh Vaziri

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Hepatosplenic T cell lymphoma (HSTCL) is a rare subtype of peripheral non-Hodgkin lymphoma, of which 20% of cases are associated with chronic immunosuppression. It often occurs in patients with inflammatory bowel disease treated with immunomodulating medications such a thiopurines or TNF-alpha inhibitors. Cytopenias are commonly seen but autoimmune hemolytic anemia (AIHA) is rare. Here we present a young male with longstanding ulcerative colitis on chronic azathioprine, exhibiting several rare features of HSTCL. He initially presented with refractory AIHA, thrombocytopenia, and massive splenomegaly, requiring splenectomy. Histologic examination of his spleen confirmed diagnosis of HSTCL. Approximately 3 months after diagnosis, he was found to have leukemic transformation, representing a secondary malignancy.
Literatur
1.
Zurück zum Zitat Visnyei K, Grossbard ML, Shapira I. Hepatosplenic γδ T-cell lymphoma: an overview. Clin Lymphoma Myeloma Leuk. 2013;13:360–9.CrossRefPubMed Visnyei K, Grossbard ML, Shapira I. Hepatosplenic γδ T-cell lymphoma: an overview. Clin Lymphoma Myeloma Leuk. 2013;13:360–9.CrossRefPubMed
2.
Zurück zum Zitat Shi Y, Wang E. Heaptosplenic T-Cell, Lymphoma. A clinicopathologic review with an emphasis on diagnostic differential from other T-cell/natural killer-cell neoplasms. Arch Pathol Lab Med. 2015;139:1173–80.CrossRefPubMed Shi Y, Wang E. Heaptosplenic T-Cell, Lymphoma. A clinicopathologic review with an emphasis on diagnostic differential from other T-cell/natural killer-cell neoplasms. Arch Pathol Lab Med. 2015;139:1173–80.CrossRefPubMed
3.
Zurück zum Zitat Ferreri AJ, Govi S, Pileri SA. Heaptosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol. 2012;83:283–92.CrossRefPubMed Ferreri AJ, Govi S, Pileri SA. Heaptosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol. 2012;83:283–92.CrossRefPubMed
4.
Zurück zum Zitat Montgomery M, van Santen MM, Biemond BJ, et al. Hepatosplenic T-cell lymphoma: a population-based study assessing incidence and associate with immune-mediated disease. Gastroenterol Hepatol. 2015;11:160–3. Montgomery M, van Santen MM, Biemond BJ, et al. Hepatosplenic T-cell lymphoma: a population-based study assessing incidence and associate with immune-mediated disease. Gastroenterol Hepatol. 2015;11:160–3.
5.
Zurück zum Zitat Ibrahim FA, Shanmugam V, Amer A, et al. An unusual case of hepatosplenic αβ T-cell lymphoma presenting with Coomb’s negative hemolytic anemia. Clin Med Insights Oncol. 2015;9:123–8.CrossRefPubMedPubMedCentral Ibrahim FA, Shanmugam V, Amer A, et al. An unusual case of hepatosplenic αβ T-cell lymphoma presenting with Coomb’s negative hemolytic anemia. Clin Med Insights Oncol. 2015;9:123–8.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Thai A, Prindiville T. Heaptosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis. 2010;4:511–22.CrossRefPubMed Thai A, Prindiville T. Heaptosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis. 2010;4:511–22.CrossRefPubMed
7.
Zurück zum Zitat Parakkal D, Sifuentes H, Semer R, et al. Hepatosplenic T-cell lymphoma in patients receiving TNF-alpha inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol. 2011;23:1150–6.CrossRefPubMed Parakkal D, Sifuentes H, Semer R, et al. Hepatosplenic T-cell lymphoma in patients receiving TNF-alpha inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol. 2011;23:1150–6.CrossRefPubMed
8.
Zurück zum Zitat Rashidi A, Lee ME, Fisher SI. Hepatosplenic αβ T-Cell lymphoma associated with azathrioprine therapy. Int J Hematol. 2012;95:582–94.CrossRef Rashidi A, Lee ME, Fisher SI. Hepatosplenic αβ T-Cell lymphoma associated with azathrioprine therapy. Int J Hematol. 2012;95:582–94.CrossRef
9.
Zurück zum Zitat Selvaraj SA, Chairez E, Wilson LM, et al. Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn’s disease medications and heptosplenic T-cell lymphoma. Syst Rev. 2013;2:53.CrossRefPubMedPubMedCentral Selvaraj SA, Chairez E, Wilson LM, et al. Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn’s disease medications and heptosplenic T-cell lymphoma. Syst Rev. 2013;2:53.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Sallah S, Smith SV, Lony LC, et al. Gamma/delta T-cell hepatosplenic lymphoma: review of the literature, diagnosis by flow cytometry and concomitant autoimmune hemolytic anemia. Ann Hematol. 1997;74:139–42.CrossRefPubMed Sallah S, Smith SV, Lony LC, et al. Gamma/delta T-cell hepatosplenic lymphoma: review of the literature, diagnosis by flow cytometry and concomitant autoimmune hemolytic anemia. Ann Hematol. 1997;74:139–42.CrossRefPubMed
11.
Zurück zum Zitat Pouderoux P, Gris JC, Pignodel C, et al. Primary sinusoidal lymphoma of the liver revealed by autoimmune hemolytic anemia. Gastroenterol Clin Biol. 1997;21:514–8.PubMed Pouderoux P, Gris JC, Pignodel C, et al. Primary sinusoidal lymphoma of the liver revealed by autoimmune hemolytic anemia. Gastroenterol Clin Biol. 1997;21:514–8.PubMed
12.
Zurück zum Zitat Motta G, Vianello F, Menin C, et al. Hepatosplenic gammadelta T-cell lymphoma presenting with immune-mediated thrombocytopenia and hemolytic anemia (Evans; syndrome). Am J Hematol. 2002;69:272–6.CrossRefPubMed Motta G, Vianello F, Menin C, et al. Hepatosplenic gammadelta T-cell lymphoma presenting with immune-mediated thrombocytopenia and hemolytic anemia (Evans; syndrome). Am J Hematol. 2002;69:272–6.CrossRefPubMed
13.
Zurück zum Zitat Lai R, Larratt LM, Etches W, et al. Hepatosplenic T-cell lymphoma and alphabeta lineage in a 16-year-old boy presenting with hemolytic anemia and thrombocytopenia. Am J Surg Pathol. 2000;24:459–63.CrossRefPubMed Lai R, Larratt LM, Etches W, et al. Hepatosplenic T-cell lymphoma and alphabeta lineage in a 16-year-old boy presenting with hemolytic anemia and thrombocytopenia. Am J Surg Pathol. 2000;24:459–63.CrossRefPubMed
14.
Zurück zum Zitat Mastovich S, Ratech H, Ware RE, et al. Hepatosplenic T-cell lymphoma: an unusual case of gamma delta T-cell lymphoma with a blast-like terminal transformation. Hum Pathol. 1994;25:102–8.CrossRefPubMed Mastovich S, Ratech H, Ware RE, et al. Hepatosplenic T-cell lymphoma: an unusual case of gamma delta T-cell lymphoma with a blast-like terminal transformation. Hum Pathol. 1994;25:102–8.CrossRefPubMed
15.
Zurück zum Zitat Benedek Lazar R, Kopeczi JB, Tunyogi AB, et al. Histopathological, immunophenotypic and clinical particularities and evolution of a case of hepatosplenic T-cell lymphoma in transformation to leukemia. Rom J Morphol Embryol. 2013;54:1135–59.PubMed Benedek Lazar R, Kopeczi JB, Tunyogi AB, et al. Histopathological, immunophenotypic and clinical particularities and evolution of a case of hepatosplenic T-cell lymphoma in transformation to leukemia. Rom J Morphol Embryol. 2013;54:1135–59.PubMed
16.
Zurück zum Zitat Park IG, Suh CW, Hur JR, et al. A case of a young woman with hepatosplenic gammadelta T-cell lymphoma. Cancer Res Treat. 2001;33:264–8.CrossRefPubMed Park IG, Suh CW, Hur JR, et al. A case of a young woman with hepatosplenic gammadelta T-cell lymphoma. Cancer Res Treat. 2001;33:264–8.CrossRefPubMed
17.
Zurück zum Zitat Steurer M, Stauder R, Grunewald K, et al. Hepatosplenic gamma deltaT-cell lymphoma with leukemic course after renal transplantation. Hum Pathol. 2002;33:253–8.CrossRefPubMed Steurer M, Stauder R, Grunewald K, et al. Hepatosplenic gamma deltaT-cell lymphoma with leukemic course after renal transplantation. Hum Pathol. 2002;33:253–8.CrossRefPubMed
18.
Zurück zum Zitat Gopcsa L, Banyai A, Tamaska J, et al. Hepatosplenic gamma delta T-cell lymphoma with leukemic phase successfully treated with 2-chlorodeoxyadenosine. Haematologia. 2002;32:519–27.PubMed Gopcsa L, Banyai A, Tamaska J, et al. Hepatosplenic gamma delta T-cell lymphoma with leukemic phase successfully treated with 2-chlorodeoxyadenosine. Haematologia. 2002;32:519–27.PubMed
19.
Zurück zum Zitat Sharma S, Sreedharanunni S, Sachdeva MUC, et al. Hepatosplenic T-Cell lymphoma: a population-based study assessing incidence and association with immune-mediated disease. Gastroenterol Hepatol. 2015;11:160–3. Sharma S, Sreedharanunni S, Sachdeva MUC, et al. Hepatosplenic T-Cell lymphoma: a population-based study assessing incidence and association with immune-mediated disease. Gastroenterol Hepatol. 2015;11:160–3.
20.
Zurück zum Zitat Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009;58:1427–36.CrossRefPubMed Sokol H, Beaugerie L. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009;58:1427–36.CrossRefPubMed
21.
Zurück zum Zitat Basic Kinda S, Durakovic N, Dotlic S, et al. Heopatosplenic αβ T-Cell Lymphoma arising after long-term azathioprine therapy successfully treated with allogeneic bone marrow transplant. Leuk Lymphoma. 2013;54:1334–5.CrossRefPubMed Basic Kinda S, Durakovic N, Dotlic S, et al. Heopatosplenic αβ T-Cell Lymphoma arising after long-term azathioprine therapy successfully treated with allogeneic bone marrow transplant. Leuk Lymphoma. 2013;54:1334–5.CrossRefPubMed
22.
Zurück zum Zitat Cholongitas E, Pipili C, Kaklamanis L, et al. Is there any association between non-Hodgkin’s lymphoma and primary sclerosing cholangitis/autoimmune hepatitis overlap syndrome? Dig Dis Sci. 2008;53:867–8.CrossRefPubMed Cholongitas E, Pipili C, Kaklamanis L, et al. Is there any association between non-Hodgkin’s lymphoma and primary sclerosing cholangitis/autoimmune hepatitis overlap syndrome? Dig Dis Sci. 2008;53:867–8.CrossRefPubMed
23.
Zurück zum Zitat Werner M, Almer S, Prytz H, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow up in 473 Swedish patients. J Hepatol. 2009;50:388–93.CrossRefPubMed Werner M, Almer S, Prytz H, et al. Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow up in 473 Swedish patients. J Hepatol. 2009;50:388–93.CrossRefPubMed
24.
Zurück zum Zitat Subramaniam K, Yeung D, Grimpen F, et al. Heaptosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks? Intern Med J. 2014;44:287–90.CrossRefPubMed Subramaniam K, Yeung D, Grimpen F, et al. Heaptosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks? Intern Med J. 2014;44:287–90.CrossRefPubMed
25.
Zurück zum Zitat Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99–105.CrossRefPubMed Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99–105.CrossRefPubMed
26.
Zurück zum Zitat Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.CrossRefPubMed Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.CrossRefPubMed
27.
Zurück zum Zitat Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–86.CrossRefPubMedPubMedCentral Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–86.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Pozadzides JV, Pro B. Hepatosplenic T-Cell lymphoma and TNF-alpha inhibitors. Expert Rev Hematol. 2009;2:611–4.CrossRefPubMed Pozadzides JV, Pro B. Hepatosplenic T-Cell lymphoma and TNF-alpha inhibitors. Expert Rev Hematol. 2009;2:611–4.CrossRefPubMed
Metadaten
Titel
Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction
verfasst von
Marianna Mavilia
Agnes McAuliffe
Safina Hafeez
Haleh Vaziri
Publikationsdatum
15.05.2018
Verlag
Springer Japan
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 5/2018
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-018-0869-x

Weitere Artikel der Ausgabe 5/2018

Clinical Journal of Gastroenterology 5/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.